Based on these promising results,31 a phase II study (NCT 04829604) is ongoing to evaluate the efficacy and safety of ARX788 in HER2-positive breast cancer patients with heavy pre-treatment, including T-DXd. Here, ERBB2 is linked to breast carcinoma.